Skip to main content
Premium Trial:

Request an Annual Quote

ParAllele Signs Genotyping Collaboration with Merck, Gives NCI Lab Access to SNP Technology

NEW YORK, May 12 (GenomeWeb News) - ParAllele BioScience has started a pharmacogenomics collaboration with Merck, and has given the National Cancer Institute early access to its SNP genotyping platform, the company said today.

 

Under the agreement with Merck, South San Francisco-based ParAllele will determine genetic variations in a number of genes chosen by Merck using its SNP genotyping platform. Merck will fund the study, which is the second collaboration between the companies.

 

ParAllele's MegAllele SNP genotyping platform will also be used by the Laboratory of Genomic Diversity at NCI-Frederick, an early access customer. The technology does not require the DNA around each SNP to be amplified prior to analysis, according to the company.

 

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.